Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (INCEPTION)

  • STATUS
    Not Recruiting
  • End date
    Mar 29, 2023
  • participants needed
    159
  • sponsor
    Amgen
Updated on 14 September 2022
Investigator
Amgen Call Center
Primary Contact
Allergy Research Canada Incorporated (7.0 mi away) Contact
+75 other location

Summary

The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).

Details
Condition Chronic Spontaneous Urticaria
Treatment Placebo, omalizumab, Tezepelumab Dose 1, Tezepelumab Dose 2
Clinical Study IdentifierNCT04833855
SponsorAmgen
Last Modified on14 September 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note